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Abstract  
Aims: Analyse effects of patient characteristics and different OAD use on standardised clinical outcomes 
in type 2 diabetes patients initiating insulin glargine 100 U/ml (Gla-100).  
Materials and Methods: Patient-level data were analysed from 16 randomised, treat-to-target clinical 
trials that added Gla-100 to existing metformin (MET), sulfonylurea (SU), or metformin plus sulfonylurea 
(MET+SU) in insulin-naïve patients inadequately controlled on oral therapy and followed for ≥24 weeks. 
Change in glycated haemoglobin A1c (HbA1c) from baseline to Week 24, other glycaemic endpoints, and 
incidence of hypoglycaemia (overall, nocturnal, and severe) were analysed by age (<65 vs. ≥65 years), 
gender (male vs. female), body mass index (BMI; <25 vs. ≥25 to <30 vs. >30 kg/m2), and concomitant 
OAD (MET vs. SU vs. MET+SU). 
Results: At baseline, overall population (N=3.188) had a mean age of 57.7 years, BMI 30.5 kg/m2, HbA1c 
8.7%, fasting plasma glucose 192 mg/dl, 52.7% were male.  Younger and older patients had similar 
HbA1c reductions with Gla-100 and similar risk of hypoglycaemia. Females and patients with BMI <25 
kg/m2 were less likely to achieve HbA1c targets and more likely to experience hypoglycaemia, regardless 
of concomitant OAD. Adding Gla-100 to SU therapy (alone or combination with MET) increased 
hypoglycaemia risk across all analyses.  
Conclusions: Our data suggest that T2DM female patients and normal-weight patients treated with Gla-
100 and metformin ±sulfonylurea are less likely to achieve glycaemic targets and therefore, may require 
more clinical attention. Addition of Gla-100 to SU regimens may increase hypoglycaemia risk irrespective 
of age, gender or BMI. 
Introduction 
The number of people with diabetes has grown almost fourfold in recent decades to an estimated 422 
million in 2014 [1], due largely to type 2 diabetes (T2D), which is characterised by progressive insulin 
resistance, insulin deficiency, and defects in beta cell function [2]. Owing to the progressive nature of 
T2D, patients who are treated initially with oral antidiabetes drugs (OADs) may need to initiate basal 
insulin to maintain overall glucose control and minimise risk of developing diabetes-related 
complications [3,4].  
Present guidelines recommend intensification of therapy in patients inadequately controlled with 
current treatments, proposing basal insulin as one of the suitable options. [3,4] Yet the presence of 
different patient characteristics, types of studies, types of combination therapies, and definitions for 
hypoglycaemia—to name just a few confounding factors—may confuse the issue. Further, the position 
statement of the American Diabetes Association (ADA) and the European Association for the Study of 
Diabetes (EASD) on the management of hyperglycaemia in T2D emphasises the importance of tailoring 
therapy for adult patients with T2D [3,4], and states that patient factors such as age, gender, and body 
mass index (BMI) should be taken into account when making treatment decisions. The guidelines state 
that special care is required in prescribing and monitoring pharmacological treatment in older adults 
[3,4]. Separately, previous studies have suggested that females with T2D are less likely to reach 
glycaemic targets and have a higher risk of hypoglycaemia with insulin therapy compared with males, 
suggesting that gender may play a role when tailoring therapy for individual patients [5,6]. Previous 
studies also have suggested that BMI may affect the glycated haemoglobin A1c (HbA1c) level achieved 
and hypoglycaemia risk in patients with T2D [7,8]. Clear guidance is needed to help physicians weigh 
patient characteristics when initiating basal insulin. 
 
The objective of this study was to analyse patient-level data comparing standardised clinical 
outcomes in insulin-naïve patients with T2D adding insulin glargine 100 U/ml (Gla-100) to existing OADs 
according to these important variables- age, gender, BMI category, and type of concomitant OAD use. 
 
Methods 
Study selection 
To be eligible for inclusion in this analysis, studies had to be prospective, randomised, controlled treat-
to-target trials (target fasting plasma glucose [FPG] level ≤100 mg/dl) with a duration of ≥24 weeks for 
which safety population patient-level data were available for analysis. This last criterion therefore 
limited studies to those published by Sanofi. All the Sanofi-sponsored studies fulfilling the inclusion 
criteria were included in the analysis. Inclusion criteria were: Treat-to-target with protocol driven 
titration and an FPG target of <100 mg/dL, study duration >=24 weeks, T2D patients with glargine in 
combination with SU, Met or SU+Met, collection of sufficient hypoglycaemia data. No imputation was 
used, only data was included captured within the visit window. Patients were insulin-naive adults with 
T2D, adding Gla-100 to their current oral therapy. No data was used from patients requiring bolus 
insulin. Only bedtime glargine regimes were used for calculations. A total of 16 studies fulfilled all of the 
inclusion criteria (Supplementary Table 1) [9–24]. 
 
Endpoints 
Efﬁcacy endpoints evaluated included change in HbA1c level from baseline to Week 24, percentage of 
patients achieving HbA1c <7.0% at Week 24, and change in FPG from baseline to Week 24. Other 
endpoints included the percentage of patients achieving HbA1c <7.0% without overall, nocturnal, or 
severe hypoglycaemia; insulin dose; and weight change from baseline. Hypoglycaemia was defined as 
overall (with plasma glucose [PG] <70 mg/dl or requiring third-party assistance); nocturnal (events 
occurring between 0:01 AM and 5:59 AM with PG <70 mg/dl); severe (events requiring third-party 
assistance); and nocturnal severe (events occurring between 0:01 AM and 5:59 AM requiring third-party 
assistance). 
 
Statistical analyses 
Standardised patient-level data were pooled from the identified studies. Baseline and Week 24 patient 
characteristics were reported using descriptive statistics. The effects of demographic and baseline 
characteristics such as younger vs. older age (<65 vs. ≥65 years), gender (male vs. female), BMI category 
(normal [<25 kg/m2], overweight [≥25 to <30 kg/m2], and obese [≥30 kg/m2]), duration of diabetes, 
HbA1c, FPG, starting insulin dose (IU/kg), and concomitant OAD received (metformin [MET], a 
sulfonylurea [SU], or MET+SU) were examined using analysis of covariance (ANCOVA) models for HbA1c, 
FPG, and weight change from baseline. Logistic regression (PROC GENMOD, binomial distribution, logit 
link) was used for the percentage of patients reaching HbA1c <7.0% or FPG ≤100 mg/dl at endpoint. 
Adjusted hypoglycaemia incidence (percentage of patients with ≥1 event) was derived using logistic 
regression (PROC GENMOD, binomial distribution, logit link), and adjusted event rates (events/patient-
year) were derived using negative binomial regression (PROC GENMOD, negative binomial distribution, 
log link); data were adjusted for age, gender, duration of diabetes, BMI, baseline HbA1c, baseline FPG, 
baseline insulin dose, and concomitant OAD. The corresponding baseline value was also included in the 
models for efficacy variables. All models also included OAD groups and study. 
 
Results 
Patients 
Overall, 3188 patients from 16 studies were included in this analysis. Patient demographics and clinical 
characteristics are summarised here (full data of the subgroups are in Supplementary Table 2). In the 
overall population, 52.7% were male, mean age was 57.7 years, and T2D duration was 9.0 years. Mean 
weight at baseline was 86.0 kg, and mean BMI was 30.5 kg/m2. Mean HbA1c at baseline was 8.7% and 
FPG 192.1 mg/dl. Gla-100 was added to MET in 644 patients, to SU in 920 patients, and to MET+SU in 
1624 patients. 
 With regards to age at baseline (Supplementary Table 2A), 75.6% of patients were aged <65 years 
and 24.4% were aged ≥65 years. Younger patients had shorter mean duration of T2D, higher weight and 
BMI, and slightly higher HbA1c and FPG than older patients. The mean starting dose of Gla-100 was 
similar in both age groups. 
 
Mean age, duration of T2D, and HbA1c were the same for males and females (Supplementary Table 
2B). Mean FPG was slightly higher among males than females. The mean starting dose of Gla-100 was 
similar in both genders.   
 
Of patients with BMI data available at baseline (n=3187), (Supplementary Table 2C), BMI category was 
normal in 11.5%, overweight in 38.1%, and obese in 50.4% patients. Patients with a lower BMI had a 
longer duration of T2D. Baseline HbA1c levels were similar across all BMI categories, and FPG was 
highest in overweight patients; normal and obese patients had remarkably similar FPG. Initial Gla-100 
dose was highest among normal and lowest among obese patients. 
 
Efficacy 
All analyses compared baseline with results at 24 weeks. In addition, separate analyses looked at 
patients by age, gender, and BMI regardless of the type of OAD used, and by age, gender, and BMI 
stratified by the type of OAD used.  
 
In the overall study population, mean HbA1c decreased from 8.74% at baseline to 7.19% at Week 
24. Age (p=0.003), male gender (p<0.001), and baseline FPG (p=0.008) were negatively related to HbA1c 
at endpoint. Baseline HbA1c (p<0.001), diabetes duration (p<0.001), and treatment with SU only (vs. 
MET) (p=0.007) were positively related to HbA1c at endpoint. Overall, 45.6% of patients reached the 
target HbA1c of <7.0%.  
FPG decreased from 191.7 to 118.1 mg/dl. Age (p<0.001) and insulin starting dose (p=0.001) were 
negatively related to FPG at Week 24, and baseline BMI (p=0.002), use of SU only (p<0.001), or MET+SU 
(p=0.002) (vs. MET) were positively related to endpoint FPG. Overall, 34.7% of patients achieved the 
target FPG of ≤100 mg/dl. 
 
Summary of patients by age revealed that younger patients had a slightly greater mean reduction in 
HbA1c compared with older patients regardless of concomitant OAD (Figure 1A), whereas age had little 
impact on mean reductions in FPG at Week 24 (Figure 1B). Mean reductions in FPG for patients using SU 
only or MET+SU did not differ by age. However, among patients using MET only, younger patients had 
greater mean reductions in FPG than those aged ≥65 years (Figure 1B). The proportion of patients in 
varying groups reaching HbA1c <7% are depicted in Supplementary Table 3. 
 
Summarised by gender, mean reductions in HbA1c from baseline to Week 24 were lower in females 
than in males (Figure 2A). Mean FPG at Week 24 was similar in males and females, regardless of 
concomitant OAD (Figure 2B). When summarised by concomitant OAD, females had slightly smaller 
reductions in HbA1c than men, except for patients using SU only (Figure 2A).  
 
Summary of patients by BMI category revealed that mean changes in HbA1c from baseline to Week 
24 were similar across BMI categories and according to concomitant OAD use. However, a smaller 
percentage of patients in the normal BMI category achieved HbA1c <7.0% at Week 24 versus the 
overweight and obese categories; this pattern also was seen regardless of the concomitant OAD used 
(Supplementary Figure). Mean changes in FPG from baseline to Week 24 differed according to BMI 
category, with larger reductions observed in patients in the normal category versus the overweight and 
obese categories; consequently, FPG levels at Week 24 were lower in patients in the normal category 
and higher in patients in the overweight and obese categories (109.3 vs. 116.6 vs. 121.2 mg/dl, 
respectively). 
 
Hypoglycaemia 
Age had little effect on the incidence (Figure 3A) and event rates (Figure 3B) of overall, nocturnal, and 
severe hypoglycaemia, which were comparable in younger and older patients. Age (p=0.02), baseline 
BMI (p<0.001), and HbA1c (p=0.003) were negatively associated, and duration of disease (p=0.004), 
insulin starting dose (p<0.001), SU only (p=0.002), and ME+SU (p=0.001) (vs. MET) were positively 
associated with overall hypoglycaemia incidence. Age (p=0.023), gender (male vs. female) (p=0.012), 
baseline BMI (p<0.001) and baseline HbA1c (p=0.002) were negatively associated, and duration of 
diabetes (p=0.009), insulin starting dose (p<0.001), SU only (p<0.001), and MET+SU (p<0.001) (vs. MET) 
were positively associated with the event rate of overall hypoglycaemia. 
 
Overall hypoglycaemia incidence was similar in both age groups, regardless of concomitant OAD. 
The incidence of nocturnal hypoglycaemia was higher in older patients using SU only and in younger 
patients using MET+SU. The incidence of severe hypoglycaemia was mostly similar between younger 
and older patients regardless of OAD group, except that the incidence was higher among younger 
patients using MET only. The event rate for overall and nocturnal hypoglycaemia was highest among 
patients using MET+SU, regardless of age, followed by patients using SU only, with a slightly higher rate 
in older patients versus younger patients 
 
When summarised by gender, the incidence and event rates of overall and nocturnal severe 
hypoglycaemia and the event rates of overall, nocturnal, and nocturnal severe hypoglycaemia were 
significantly higher in females than males (Figure 4). This pattern generally was repeated when analysed 
by concomitant OAD. In all cases, the incidence of hypoglycaemia was at least slightly higher in females 
than in males. The difference was most pronounced among patients using SU only.  
 
In the summary of patients by BMI category, the hypoglycaemia incidence and event rates were 
highest in patients in the normal BMI category, irrespective of the concomitant OAD used (Figure 5). 
When analysed by concomitant OAD, overall hypoglycaemia incidence was highest in patients taking 
MET+SU regardless of BMI category; hypoglycaemia incidence in the patients in the normal BMI 
category taking MET only or SU only were similar to one another, but in each case higher than in 
patients in the overweight and obese BMI categories. Of note, the incidence of overall hypoglycaemia 
among patients in the obese BMI category was higher in those taking SU only (33.43%) than those taking 
MET only (27.20%). Overall hypoglycaemia event rates were higher in patients in the normal BMI 
category taking SU only (9.67 events/patient-year) or MET+SU (10.03 events/patient-year) versus MET 
only (6.16 events/patient-year). For patients in the overweight and obese BMI categories, 
hypoglycaemia event rates were highest in patients taking MET+SU, followed by patients taking SU only, 
and lowest in patients taking MET only. 
 
Body weight and insulin dose 
In the overall patient cohort, mean body weight increased from 85.9 kg to 87.8 kg. Age (p<0.001) and 
baseline BMI (p=0.028) were negatively associated, and baseline HbA1c (p<0.001), baseline FPG, and 
starting dose (p<0.001, each), SU only (p<0.001) and MET+SU (p=0.006) (vs. MET) were positively 
associated with weight at endpoint. The mean insulin dose increased from 0.16 to 0.43 IU/kg. Age and 
duration (p<0.001, each) and MET+SU (p=0.001 vs. MET) were negatively associated, and baseline BMI 
and FPG (p<0.001, each), baseline HbA1c (p=0.002) were positively associated with insulin dose at 
endpoint. (Supplementary Table 4) 
 Insulin dose increase was greater in younger patients compared with older patients. Mean 
(standard deviation [SD]) insulin dose increased by 0.30 (0.26) IU/kg from baseline to Week 24 in 
younger patients and by 0.18 (0.19) IU/kg in older patients. Analysis by concomitant OAD revealed that 
patients in either age group taking MET only had greater increases in insulin dose than those using SU 
only or MET+SU. Mean (SD) insulin dose increases were similar in males (0.27 [0.24] IU/kg) and females 
(0.28 [0.26] IU/kg). By concomitant OAD, insulin dose increases were highest for patients using MET 
only, regardless of gender, and lowest among those using SU only. Mean (SD) insulin dose requirements 
at Week 24 were higher among patients in the overweight (0.24 [0.22] IU/kg) and obese (0.32 [0.27] 
IU/kg) BMI categories compared with patients in the normal (0.16 [0.19] IU/kg) category.  
 
Discussion 
This was an analysis of pooled, standardised data from randomised, controlled treat-to-target trials with 
a duration of ≥24 weeks conducted in insulin-naïve adults with T2D who added Gla-100 to their current 
OAD therapy. The analysis used data from 16 different studies involving more than 3100 patients. The 
fact that Gla-100 is widely available and extensively used means that the findings of this analysis are of 
interest to a wide global audience. This analysis provides data on standardised clinical outcomes in 
patients initiating basal insulin therapy with Gla-100, taking into account the main confounders that 
have been present in clinical studies and presenting a more detailed picture with regard to age, gender, 
and BMI. 
 
In the overall study population, certain trends were revealed: First, addition of Gla-100 to any OAD 
led to significant reductions in HbA1c and FPG, allowing 45.6% of patients to achieve a target HbA1c 
<7.0%. Second, baseline factors with a significant impact on HbA1c at endpoint were age, gender, and 
baseline FPG, which had a negative association in the percentage of the specific group reaching HbA1c 
targets. Baseline HbA1c, diabetes duration, and treatment with SU only vs. MET only had a positive 
association in regards to reaching HbA1c targets. Third, although just over 40% of patients experienced 
some hypoglycaemia, severe hypoglycaemia occurred much less often in 1.99% of patients. Fourth, 
mean body weight increases with addition of Gla-100 were modest (<2 kg) in the overall cohort. Adding 
Gla-100 to MET only resulted in the highest percentage of patients achieving HbA1c <7.0%, mitigated 
weight increase, and was associated with a low incidence of hypoglycaemia. 
 
In the summary by age, Gla-100 use in older patients with T2D resulted in clinical outcomes similar 
to those in younger patients, but at lower insulin doses and with less weight gain. Severe hypoglycaemia 
was rare in both age groups and was not increased in older patients. Patients at any age were most 
likely to achieve HbA1c <7.0% without hypoglycaemia when adding Gla-100 to background MET only. 
 
The summary by gender revealed that female patients with T2D are less likely to reach glycaemic 
targets and have a higher risk of hypoglycaemia when adding basal insulin therapy to current OADs, 
particularly when adding Gla-100 to SU only or MET+SU. This finding supports previous data and 
suggests that women are more difficult to treat in terms of efficacy and safety compared with men, and 
that gender differences should be considered when tailoring treatment for individual patients [5,6]. The 
gender difference was consistent, possibly indicating a biological difference between males and females. 
Weight gain was low and similar for males and females, suggesting that weight gain is not an issue of 
particular concern when initiating Gla-100 in either gender. In both males and females, use of 
concomitant SU was associated with greater weight gain than use of concomitant MET alone. 
 
The summary by BMI category revealed that overweight and obese patients are more likely to 
reach HbA1c targets with higher insulin doses and with less hypoglycaemia than normal-BMI patients. 
This finding is in line with previous findings that low BMI is a risk factor for hypoglycaemia [25]. Weight 
gain was lower in the overweight and obese BMI categories than in the normal BMI category, suggesting 
that weight gain is not an issue of particular concern among patients with a high BMI who are initiating 
insulin; weight gain is more likely to occur in patients with a normal BMI. In the subanalysis by BMI 
category and OAD use, patients across all BMI categories starting basal insulin on background SU had 
lower HbA1c reduction, were less likely to achieve HbA1c <7.0 %, and had greater rates of 
hypoglycaemia. Background OAD had an impact on weight gain across BMI categories and tended to be 
highest among patients adding insulin to SU. 
 
What this study adds 
Many patients with T2D require treatment with insulin at some point as disease progresses yet 
there is limited information available to assist clinicians in predicting response to basal insulin therapy.  
A PubMed search of “predictors of response” and “basal insulin therapy” and “gender or BMI or age or 
OAD” yielded only seven articles, three of which were unrelated to diabetes care. The other four studies 
were observational in design and did not examine the effect of background OAD therapy on insulin 
response [26-29] and two studies included treatment with multiple insulin types [26,28].  There is no 
other analysis of pooled patient-level data from clinical trials measuring response at the same time 
point, using the same insulin type.  
 Our results are broadly consistent with some, though not all, findings from other investigations. 
One study reported higher HbA1c among females after 1 to 4 years of insulin therapy [28] whereas in 
another, gender did not predict response to insulin therapy [26]. However, our analysis demonstrated 
that women were less likely to achieve HbA1c target and more likely to experience hypoglycaemia is 
supported by the results of only two pooled analyses that examined only the effect of gender on 
glycaemic control and hypoglycaemia [5,6]. 
Consistent with our study, a survey of health care professionals (n = 1333) reported that lower BMI 
predicted worse glycemic control [8]. Conversely, two observational studies found that achieving 
glycemic goal was more likely in leaner patients [26,29] whilst another linked higher BMI to higher 
HbA1c [28].  
Unlike our study findings, four investigations reported a significant effect of age on insulin response 
[8,26,28,29]. Older age was associated with achieving glycaemic target with basal insulin at 6 months 
[29] and at 12 months [26] whilst two studies reported an association between younger age and worse 
control [8,28].  
 
Understanding hypoglycaemia 
The association of hypoglycaemia with insulin use remains one of the most important issues in T2D 
management [30]. To enable informed decisions about therapy choices for their patients with T2D, it is 
important that clinicians understand how different patient factors and existing background medications 
affect the hypoglycaemia risk associated with the initiation of basal insulin [31]. 
 
Directions for Future Research 
This analysis indicates that females compared with males patients, and those with normal BMI 
compared with overweight or obese individuals, were less likely to achieve HbA1c targets and more 
likely to develop hypoglycaemia when Gla-100 was added to background OAD therapy. Whether gender 
and body weight are associated with response to adding other basal insulin formulations, or other types 
of therapy, to background treatment including MET and/or SU is a question that needs to be addressed 
in future studies.  
Strengths and Limitations 
The number of patients included in this analysis, as well as inclusion of patients aged ≥65 years, can be 
considered a strength and lends validity to its conclusions. One of the other strengths of this analysis 
was that the definition of hypoglycaemia was defined consistently. Nonetheless, these patient data 
were drawn exclusively from clinical trial populations and, as such, were restricted to individuals who 
met the inclusion criteria for these studies. Additionally, we analysed only patients receiving 
concomitant MET, SU, or combined MET+SU, whereas today many patients with T2D receive treatment 
with other classes of oral agents or injected GLP-1 receptor agonists.  
The trials included in this analysis utilised different doses of MET and SU, and different regimens 
of Gla-100 administration (morning or bedtime). In some studies, patients received a thiazolidinedione 
or other anti-diabetes medications in addition to MET and/or SU (Supplementary Table 1). Patients in 
the trials reflected a diversity of populations, so that patient ethnicity and local clinical practice could 
have influenced results. Older adult participants recruited into the trials may have fewer comorbidities 
than those in clinical practice, including a lower incidence of cognitive dysfunction. Comorbidities and 
dementia may affect rates of hypoglycaemia in older adults [32,33]. Finally, our follow-up period in this 
analysis was limited to 24 weeks, and so could not account for differences in glycaemic control or 
hypoglycaemia that occurred in longer-term use of Gla-100 and OADs. 
 
Conclusions 
Taken together, the key message from these analyses is that when tailoring therapy for individual 
patients with T2D, women and patients within the normal BMI range are less likely to reach glycaemic 
targets and have a higher risk of hypoglycaemia when adding Gla-100 to current OAD therapy. Initiation 
of insulin therapy and ongoing management of these patients, therefore, should be carefully monitored. 
Age is less likely to be important, although factors for individual patients (e.g., polypharmacy, 
comorbidity, and advanced age) should be taken into account. A patient’s background OAD also is 
relevant, as use of concomitant SU was associated with more weight gain and hypoglycaemia, regardless 
of patient age, gender, or BMI, than use of concomitant MET. This suggests that physicians should 
consider discontinuing SU therapy when initiating Gla-100 regimen. 
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Figure 1. Baseline and week 24 HbA1c (A) and FPG (B) levels, stratified by age. Data represent mean 
(standard deviation) and includes all patients with baseline and Week 24 data available. FPG, fasting 
plasma glucose; HbA1c, glycated haemoglobin; MET, metformin; SU, sulfonylurea. 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 2. Baseline and week 24 HbA1c (A) and FPG (B) levels, stratified by gender. Data represent mean 
(standard deviation) and includes all patients with baseline and Week 24 data available. FPG, fasting 
plasma glucose; HbA1c, glycated haemoglobin; MET, metformin; SU, sulfonylurea. 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3. Incidence (A) and event rates (B) of overall (PG <70 mg/dl), nocturnal (PG <70 mg/dl), and 
severe hypoglycaemia, stratified by age. Error bars represent standard error. PG, plasma glucose. 
 
 
 
 
Figure 4. Incidence (A) and event rates (B) of overall, nocturnal and severe hypoglycaemia, stratified by 
gender. PG, plasma glucose. 
 
  
 
 
 
 
 
 
 
 
Figure 5. Hypoglycaemia event rates (overall and nocturnal with PG <70 mg/dl), by BMI category and 
OAD use. BMI, body mass index; MET, metformin; OAD, oral antidiabetes drug; SU, sulfonylurea. 
 
Suppl Figure. Percentage of patients achieving HbA1c <7.0% at week 24, by BMI category and OAD use. 
BMI, body mass index; HbA1c, glycated haemoglobin; MET, metformin; OAD, oral antidiabetes drug; SU, 
sulfonylurea. 
 
 
